EGFR and non-small cell lung carcinoma: So far, in June 2016, a liquid biopsy was approved by the FDA for use in the USA to detect EGFR mutations in plasma ctDNA and entered clinical practice for the management of non-small cell lung cancer (NSCLC) [68].